| 101 |
increased |
aryl hydrocarbon receptor activity
(GO:0004874)
|
aryl hydrocarbon receptor
(PR:000003858)
|
18: Activation, AhR
|
| 105 |
morphological change |
abnormal cardiovascular system physiology
(MP:0001544)
|
|
317: Altered, Cardiovascular development/function
|
| 106 |
increased |
gene expression
(GO:0010467)
|
prostaglandin G/H synthase 2
(PR:000013428)
|
1269: Increase, COX-2 expression
|
| 107 |
increased |
androgen receptor activity
(GO:0004882)
|
androgen receptor
(PR:000004191)
|
25: Agonism, Androgen receptor
|
| 108 |
decreased |
gene expression
(GO:0010467)
|
vitellogenins
(MESH:D014819)
|
285: Reduction, Vitellogenin synthesis in liver
|
| 110 |
decreased |
|
vitellogenins
(MESH:D014819)
|
221: Reduction, Plasma vitellogenin concentrations
|
| 111 |
decreased |
receptor-mediated endocytosis
(GO:0006898)
|
vitellogenins
(MESH:D014819)
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 112 |
decreased |
oocyte growth
(GO:0001555)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 113 |
decreased |
oocyte development
(GO:0048599)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 251 |
decreased |
gene expression
(GO:0010467)
|
carnitine O-palmitoyltransferase 1, liver isoform
(PR:000005835)
|
472: Down Regulation, CPT1A
|
| 115 |
decreased |
|
Follicle stimulating hormone
(CHEBI:81569)
|
129: Reduction, Gonadotropins, circulating concentrations
|
| 116 |
decreased |
calcium-transporting ATPase activity
(GO:0005388)
|
calcium ion-transporting ATPase complex
(GO:0090534)
|
51: Inhibition, Ca++ ATPase
|
| 117 |
increased |
|
calcium ion
(CHEBI:39124)
|
50: Increase, Ca++ (intracellular)
|
| 118 |
disrupted |
|
mitochondrial respiratory chain
(GO:0005746)
|
178: Mitochondrial electron transport chain, disrupted
|
| 120 |
increased |
reactive oxygen species biosynthetic process
(GO:1903409)
|
reactive oxygen species
(CHEBI:26523)
|
1115: Increase, Reactive oxygen species
|
| 121 |
decreased |
|
nitric oxide
(CHEBI:16480)
|
193: Decreased, Nitric Oxide
|
| 122 |
decreased |
long-term synaptic potentiation
(GO:0060291)
|
|
166: Decreased, Long-term potentiation (LTP)
|
| 124 |
decreased |
transport
(GO:0006810)
|
bile salt export pump
(PR:000003549)
|
41: Inhibition, Bile Salt Export Pump (ABCB11)
|
| 125 |
increased |
gene expression
(GO:0010467)
|
bile acid receptor
(PR:000011396)
|
288: Activation of specific nuclear receptors, Transcriptional change
|
| 126 |
increased |
|
bile
(UBERON:0001970)
|
214: Bile accumulation, Pathological condition
|
| 127 |
increased |
cytokine secretion
(GO:0050663)
|
Cytokine
(FMA:84050)
|
87: Release, Cytokine
|
| 221 |
decreased |
blood circulation
(GO:0008015)
|
blood
(UBERON:0000178)
|
298: Insufficiency, Vascular
|
| 246 |
increased |
triglyceride biosynthetic process
(GO:0019432)
|
triglyceride
(CHEBI:17855)
|
454: Increased, Triglyceride formation
|
| 197 |
increased |
Respiratory Hypersensitivity
(MESH:D012130)
|
|
313: Increase, Allergic Respiratory Hypersensitivity Response
|
| 200 |
increased |
cytokine production involved in inflammatory response
(GO:0002534)
|
|
826: Activation, Keratinocytes
|